CAMBRIDGE, Mass., Dec. 19, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR/Cas9 technology for gene editing and repair, announced today that the company will be a presenting company at Biotech Showcase 2015. Biotech Showcase is an annual conference that provides an opportunity for private and public biotechnology companies to present to investors and pharmaceutical executives concurrent with one of the industry’s largest annual investor conferences.
Intellia’s presentation will highlight the potential of CRISPR/Cas9 as a therapeutic platform, and showcase its progress in advancing lead programs toward the clinic. The presentation will take place on Tuesday, January 13, 2015 at 10:15 AM PST at the Parc 55 Wyndham in San Francisco, California.
About Intellia Therapeutics
Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR/Cas9 technology. Intellia holds exclusive access to one of the broadest intellectual property platforms available for the therapeutic use of CRISPR/Cas9. The company is advancing a broad pipeline toward clinical development, including ex vivo and in vivo approaches. Intellia closed a Series A round in 2014 led by Atlas Venture and Novartis Institute of Biomedical Research.
For information contact:
Feinstein Kean Healthcare
Gregory Kelley, (404) 836-2302